Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...

The following is a summary of “Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

5 This can cause neurological symptoms such as the following 6 ... is also observed in a smaller percentage of diffuse large B-cell lymphoma and other B-cell lymphomas. 2 Therefore, analysis ...

The study aims to evaluate the efficacy of SynKIR-310 in B-cell non-Hodgkin lymphoma subtypes such as diffuse large ... and it acts faster to alleviate cold symptoms. The light green oval soft capsule ...

Basel: Roche has announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) ...

Aspects Atypical lymphoid proliferation composed predominantly of B cells B-cell lymphoma Table 5 ... and systemic symptoms. All these features indicate that AtLP are more likely to be associated ...

Pirtobrutinib (brand name Jaypirca) could reduce progression or death risk by 46% in patients with chronic lymphocytic ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...